MedKooCat#:510211
Name:Lumacaftor
CAS#:936727-05-8
ChemicalFormula:C24H18F2N2O5
ExactMass:452.11838
MolecularWeight:452.41
ElementalAnalysis:C,63.72;H,4.01;F,8.40;N,6.19;O,17.68
Synonym:VX-809;VX809;VX809;Lumacaftor
IUPAC/ChemicalName:3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoicacid
InChiKey:UFSKUSARDNFIRC-UHFFFAOYSA-N
InChiCode:InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)
SMILESCode:O=C(O)C1=CC=CC(C2=NC(NC(C3(C4=CC=C(OC(F)(F)O5)C5=C4)CC3)=O)=CC=C2C)=C1
TechnicalData
AdditionalInformation
References
1:AroraK,NarenAP.PharmacologicalCorrectionofCysticFibrosis:MolecularMechanismsatthePlasmaMembranetoAugmentMutantCFTRFunction.CurrDrugTargets.2015Dec8.[Epubaheadofprint]PubMedPMID:26648081.
2:BrewingtonJJ,McPhailGL,ClancyJP.Lumacaftoraloneandcombinedwithivacaftor:preclinicalandclinicaltrialexperienceofF508delCFTRcorrection.ExpertRevRespirMed.2015Dec9:1-13.[Epubaheadofprint]PubMedPMID:26581802.
3:BoschB,DeBoeckK.Searchingforacureforcysticfibrosis.A25-yearquestinanutshell.EurJPediatr.2015Nov14.[Epubaheadofprint]PubMedPMID:26567541.
4:DongZW,ChenJ,RuanYC,ZhouT,ChenY,ChenY,TsangLL,ChanHC,PengYZ.CFTR-regulatedMAPK/NF-κBsignalinginpulmonaryinflammationinthermalinhalationinjury.SciRep.2015Oct30;5:15946.doi:10.1038/srep15946.PubMedPMID:26515683;PubMedCentralPMCID:PMC4626762.
5:RehmanA,BalochNU,JanahiIA.Lumacaftor-IvacaftorinPatientswithCysticFibrosisHomozygousforPhe508delCFTR.NEnglJMed.2015Oct29;373(18):1783.doi:10.1056/NEJMc1510466#SA1.PubMedPMID:26510035.
6:WainwrightCE,ElbornJS,RamseyBW.Lumacaftor-IvacaftorinPatientswithCysticFibrosisHomozygousforPhe508delCFTR.NEnglJMed.2015Oct29;373(18):1783-4.doi:10.1056/NEJMc1510466.PubMedPMID:26510034.
7:ElbornJS,RamseyB,WainwrightC,BoyleM.Responseto:'Lumacaftor/ivacaftorforpatientshomozygousforPhe508del-CFTR:shouldwecurbourenthusiasm?'byJonesandBarry.Thorax.2015Oct27.pii:thoraxjnl-2015-207611.doi:10.1136/thoraxjnl-2015-207611.[Epubaheadofprint]PubMedPMID:26506855.
8:MatthesE,GoeppJ,CarlileGW,LuoY,DejgaardK,BilletA,RobertR,ThomasDY,HanrahanJW.LowfreedrugconcentrationpreventsinhibitionofF508delCFTRfunctionalexpressionbythepotentiatorVX-770(ivacaftor).BrJPharmacol.2015Oct22.doi:10.1111/bph.13365.[Epubaheadofprint]PubMedPMID:26492939.
9:GohilK.PharmaceuticalApprovalUpdate.PT.2015Sep;40(9):567-8.PubMedPMID:26417173;PubMedCentralPMCID:PMC4571842.
10:KukK,Taylor-CousarJL.Lumacaftorandivacaftorinthemanagementofpatientswithcysticfibrosis:currentevidenceandfutureProspects.TherAdvRespirDis.2015Dec;9(6):313-26.doi:10.1177/1753465815601934.Epub2015Sep28.Review.PubMedPMID:26416827.
11:SilvermanE.Orkambi'sSlickUnveilingPutsInsurersinaBind.ManagCare.2015Aug;24(8):16-7.PubMedPMID:26399136.
12:OngT,RamseyBW.UpdateinCysticFibrosis2014.AmJRespirCritCareMed.2015Sep15;192(6):669-75.doi:10.1164/rccm.201504-0656UP.Review.PubMedPMID:26371812.
13:BaliV,LazrakA,GurojiP,FuL,MatalonS,BebokZ.AsynonymouscodonchangealtersthedrugsensitivityofΔF508cysticfibrosistransmembraneconductanceregulator.FASEBJ.2015Sep3.pii:fj.15-273714.[Epubaheadofprint]PubMedPMID:26336913.
14:GoralskiJL,DavisSD.Improvingcomplexmedicalcarewhileawaitingnext-generationCFTRpotentiatorsandcorrectors:Thecurrentpipelineoftherapeutics.PediatrPulmonol.2015Oct;50Suppl40:S66-73.doi:10.1002/ppul.23253.PubMedPMID:26335956.
15:PhuanPW,VeitG,TanJA,FinkbeinerWE,LukacsGL,VerkmanAS.PotentiatorsofDefectiveΔF508-CFTRGatingthatDoNotInterferewithCorrectorAction.MolPharmacol.2015Oct;88(4):791-9.doi:10.1124/mol.115.099689.Epub2015Aug5.PubMedPMID:26245207;PubMedCentralPMCID:PMC4576684.
16:SinhaC,ZhangW,MoonCS,ActisM,YarlagaddaS,AroraK,WoodroofeK,ClancyJP,LinS,ZiadyAG,FrizzellR,FujiiN,NarenAP.CapturingtheDirectBindingofCFTRCorrectorstoCFTRbyUsingClickchemistry.Chembiochem.2015Sep21;16(14):2017-22.doi:10.1002/cbic.201500123.Epub2015Aug11.PubMedPMID:26227551;PubMedCentralPMCID:PMC4672727.
17:FerkolT,QuintonP.PrecisionMedicine:AtWhatPrice?AmJRespirCritCareMed.2015Sep15;192(6):658-9.doi:10.1164/rccm.201507-1428ED.PubMedPMID:26207804.
18:TomatiV,SondoE,ArmirottiA,CaciE,PesceE,MariniM,GianottiA,JeonYJ,CilliM,PistorioA,MastracciL,RavazzoloR,ScholteB,RonaiZ,GaliettaLJ,PedemonteN.GeneticInhibitionOfTheUbiquitinLigaseRnf5AttenuatesPhenotypesAssociatedToF508delCysticFibrosisMutation.SciRep.2015Jul17;5:12138.doi:10.1038/srep12138.PubMedPMID:26183966;PubMedCentralPMCID:PMC4505316.
19:NauJY.[CysticFibrosis:towardagenetictreatment;ClostridiumdifficileversusClostridiumdifficile].RevMedSuisse.2015May27;11(476):1210-1.French.PubMedPMID:26182641.
20:FarinhaCM,SousaM,CanatoS,SchmidtA,UliyakinaI,AmaralMD.IncreasedefficacyofVX-809indifferentcellularsystemsresultsfromanearlystABIlizationeffectofF508del-CFTR.PharmacolResPerspect.2015Aug;3(4):e00152.doi:10.1002/prp2.152.Epub2015Jun11.PubMedPMID:26171232;PubMedCentralPMCID:PMC4492728.
